Latest QurAlis News & Updates

See the latest news and media coverage for QurAlis. We track all announcements, press releases, and industry mentions in real time, all in one place.

QurAlis

Biotechnology company developing neurodegenerative disease therapies

Latest news about QurAlis

April 30 QurAlis

QurAlis announces speakers at TargetALS Meeting

CEO Kasper Roet presents ANQUR trial data; VP Sandy Hinckley discusses QRL-101 for ALS and epilepsy.
March 25 QurAlis

QurAlis presents interim ANQUR trial data

CTO Hagen Cramer spoke at RNA Leaders Europe conference and co-hosted a workshop on RNA therapy delivery. QRL-201 aims to restore STMN2 expression in ALS patients.
March 12 QurAlis

QurAlis' CTO presents at RNA Leaders Europe

Hagen Cramer speaks on RNA delivery on March 17 and shares ANQUR trial data for QRL-201 on March 19 in Vienna.
February 23 QurAlis

QurAlis announces positive interim ANQUR trial data for QRL-201

Data show target engagement, STMN2 restoration, neurofilament reduction, and slowed ALS progression. Plans advance to Phase 3 in 2027.

February 26 ALS News Today

Experimental ALS therapy QRL-201 shows potential to slow disease decline

Experimental therapy QRL-201 shows potential to slow ALS progression by restoring a vital nerve protein. Interim Phase 1/2 data indicate that QRL-201 restores Stathmin-2 levels...
February 23 Morningstar

QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS

QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS First...
February 21 Endpoints News

QurAlis’ ALS drug sees early positive signal, but questions remain

QurAlis believes the biomarker data from the Phase 1/2 study are strong enough to move QRL-201 to a pivotal trial. But the experiment failed to...
1 December 2025 Clinical Trials Arena

QurAlis announces Phase I QRL-101 trial topline results in ALS

QurAlis has announced topline results from its Phase I proof-of-mechanism clinical trial of QRL-101 in patients with ALS.

Never miss news about QurAlis

Track QurAlis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to QurAlis and other trending companies.